IP Library Granted Patent US 12,329,902
Granted Patent B2
US 12,329,902 · App. 16/810,226 · Granted Jun 17, 2025

Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization

Inventors: Daniel Shahaf (Kibbutz Dganiya, IL); Iris Shichor (Zichron Yaakov, IL)
Assignee: SipNose Ltd.
A61M15/009A61M11/001A61M11/02A61M15/0035A61M15/08A61M2202/0208A61M2202/0225A61M2202/025A61M2202/0266A61M2202/0291A61M2202/0488A61M2205/3334A61M2205/3337A61M2210/0618A61M2210/0625A61M2210/1089A61M2210/1475
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,329,902
App. No.
16/810,226
Granted
Jun 17, 2025
Kind
B2
Abstract

A device for delivering a predetermined volume of a substance within at least one body cavity of a subject includes a predefined volume for containing the predetermined volume of the at least one substance. The device also includes a delivery end for placement in proximity to the body cavity where the delivery end includes at least one orifice of diameter D. The device further includes a valve mechanically connectable to the container, the valve having at least two configurations: (i) an active configuration in which the valve enables delivery of predetermined volume V sub [ml] of the substance and, (ii) an inactive configuration, in which the valve prevents delivery of the predetermined volume V sub [ml] of the substance from the container to the body cavity. The device also includes a fluid tight chamber configured to contain a predetermined volume V gas [ml] of pressurized gas at a predetermined pressure, P gas [barg].

Claims (50)

1. A device configured to deliver one or more substances within at least one body cavity of a subject, the device comprising:

at least one vial comprising a predetermined volume V sub [ml or mg] of said substances;

said at least one vial having a fluid inlet and a fluid discharging outlet, the fluid discharging outlet having a diameter D [mm] and being configured for placement in proximity to said at least one body cavity;

said fluid inlet configured by means of size and shape to interface in a sealable manner with at least one puncturing member, the at least one puncturing member being configured to pierce the fluid inlet upon coupling to the fluid inlet, thereby providing said one or more substances in a fluid communication, via at least one valve, with at least one chamber configured to accept pressurized fluid at a volume V PF [ml] and a pressure P PF [barg];

said valve is commutable from a CLOSED CONFIGURATION to an OPEN CONFIGURATION within a period of time dT, the period of time dT being less than 500 milliseconds;

wherein when the valve is in said OPEN CONFIGURATION, said pressurized fluid flows from said at least one chamber via said fluid inlet and entrains said one or more substances such that the pressurized fluid erupts via said fluid discharging outlet to within said at least one body cavity in the form of an aerosol;

wherein a release time dT release of said V sub [ml or mg] of said one or more substances and said V PF [ml] of said pressurized fluid is less than 500 milliseconds;

wherein a composition of the aerosol exiting said fluid discharging outlet into said at least one body cavity forms a bi-modal spray pattern, the bi-modal spray pattern having a first plume angle of less than 25° in a first portion and a second plume angle of approximately 35°±10° in a second portion.

2. The device of claim 1 , wherein said at least one chamber comprises a port fluidly connectable to the exterior of said device, said port configured such that said at least one substance is insertable into said at least one chamber via said port.

3. The device of claim 2 , wherein said device comprises a port cover configured to provide an air-tight closure for said port, said port cover being configured to articulate relative to the device via at least one of sliding along said device, rotating around said device, or rotating about a hinge on an exterior of said device.

4. The device of claim 1 , wherein said vial is blow-molded, filled and sealed in a continuous manufacturing process.

5. The device of claim 1 , wherein a velocity of particles within the aerosol ranges from 5 m/s to 50 m/s.

6. The device of claim 1 , wherein said at least one substance comprises at least one of a gas, a liquid, a powder, an aerosol, a slurry, a gel, or a suspension.

7. The device of claim 1 , wherein the at least one chamber is configured to contain a predetermined volume V gas [ml] of pressurized gas at a predetermined pressure P gas ; and

wherein at least one of the following is true:

a) the device is configured to deliver the one or more substances within at least one of a nasal cavity, a mouth, a throat, an ear, a vagina, a rectum, a urethra;

b) said pressurized gas is selected from a group consisting of air, nitrogen, oxygen, carbon dioxide, helium, neon, xenon and any combination thereof;

c) during dispensing of said at least one substance, a mixture of said predetermined volume V gas [ml] of said pressurized gas with said predetermined volume V sub [ml or mg] of said at least one substance entrained within it forms the aerosol;

said aerosol having a predetermined distribution, said distribution being either homogeneous or heterogeneous, said heterogeneous distribution being selected from a group consisting of: an arbitrary distribution, a distribution in which a density of said at least one substance within said mixture follows a predetermined pattern, and any combination thereof; wherein at least one characteristic of the aerosol is based on at least one characteristic of the device, the at least one characteristic of the aerosol comprising at least one of a particle size, particle shape, particle distribution, and the at least one characteristic of the device comprising at least one of said predetermined volume of said pressurized gas, said predetermined volume of said substance, said predetermined pressure of said pressurized gas, or said diameter D [mm] of the fluid discharging outlet;

d) at least one said substance is stored under one of the followings: an inert atmosphere; under vacuum and a pressure above ambient pressure to prevent reactions during storage;

e) when the at least one substance is administered nasally via the device, a dose-response curve of a concentration of the at least one substance within a brain of the subject is substantially linear and

f) when the at least one substance is administered nasally via the device, a fit of a dose-response curve of a concentration of the at least one substance within a brain of the subject is logarithmic, parabolic, exponential, sigmoid, power-low, or any combination thereof.

8. The device of claim 1 , wherein said vial is a capsule having a main longitudinal axis, said capsule comprising a number n of compartments, said capsule configured to contain said predetermined volume V sub [ml or mg] of said at least one substance, said volume V sub [ml or mg] of said at least one substance containable in at least one of said n compartments; at least one of the following being true:

a) the number n of said compartments is an integer greater than or equal to 1; at least one of the compartments has a cross-section with a shape selected from a group consisting of: wedge shaped, circular, oval, elliptical, polygonal, annular, and any combination thereof;

b) for said number n of compartments being an integer greater than 1, at least two of said compartments have different volumes;

c) for said number n of compartments being an integer greater than 1, at least two of said compartments have the same volume;

d) for said number n of compartments being an integer greater than 1, at least two of said compartments have different cross-sectional areas;

e) for said number n of compartments being an integer greater than 1, at least two of said compartments have a same cross-sectional area;

f) for said number n of compartments being an integer greater than 1, at least two of said compartments contain different substances;

g) for said number n of compartments being an integer greater than 1, at least two of said compartments contain the same substance;

h) for said number n of compartments being an integer greater than 1, at least two said compartments are disposed coaxially around said main longitudinal axis of said capsule;

i) for said number n of compartments being an integer greater than 1, at least two said compartments are disposed sequentially along said main longitudinal axis of said capsule;

j) for said number n of compartments greater than 1, said at least one substance mixes during said dispensing; and

k) for said number n of compartments greater than 1, said at least one substance reacts during said dispensing.

9. The device of claim 1 , wherein said pressurized fluid entrains said substance in a pulsed manner, such that a plurality of portions of V PF are emitted via said fluid discharging outlet to within said at least one body cavity.

10. The device of claim 1 , wherein said substance is selected from a group consisting of: proteins; stem-cells; cells, organs, portions, extracts, and isolations thereof; macromolecules; RNA or other genes and proteins-encoding materials; neurotransmitters; receptor antagonists; hormones; Ketamine; commercially available by Lilly (US) Baqsimi product; Glucagon; substrates to treat one of the following: anaphylaxis, Parkinson, seizures and opioid overdose; epinephrine; atropine; metoclopramide; commercially available Naloxone or Narcan products; Esketamine (Spravato); Radicava [edaravone]; Ingrezza [valbenazine], Austedo [deutetrabenazine]; Midazolam, Insulin, Ocrevus [ocrelizumab]; Xadago [safinamide]; Spinraza [nusinersen]; Zinbryta [daclizumab]; Nuplazid [pimavanserin], Aristada [aripiprazole lauroxil]; Vraylar [cariprazine]; Rexulti [brexpiprazole]; Aptiom [eslicarbazepine acetate]; Vizamyl [flutemetamol F 18 injection]; Brintellix [vortioxetine], Tecfidera [dimethyl fumarate]; Dotarem [gadoterate meglumine]; Antibody mediated brain targeting drug delivery including aducanumab, gantenerumab, bapineuzumab, solanezumab, ofatumumab CD20, BIIB033, LCN2, HMGBI; insulin; oxytocin; orexin-A; leptin; benzodiazepine i.e. midazolam; naloxone; perillyl alcohol; camptothecin; phytochemicals including curcumin and chrysin; nucleotides; olanzapine; risperidone; Venlafaxin; GDF-5; zonisamide; ropinirole; plant-originated and synthetically-produced terpenes and cannabinoids, including THC and CBD; valproric acid; rivastigmine; estradiol; topiramate or an equivalent preparation comprising CAS No. 97240-79-4; MFSD2 or MFSD2A or sodium-dependent lysophosphatidylcholine symporter; and any esters, salts, derivatives, mixtures, combinations thereof, with or without a carrier, liposomes, lyophilic or watermiscible solvents, surfactants, cells, cells fractions, cells secreation/secrotomes at a therapeutically effective concentration.

11. The device of claim 1 , wherein when the delivery of said predetermined volume V sub [ml or mg] of said at least one substance and said predetermined volume V PF of said pressurized gas through said fluid discharging outlet of diameter D [mm] in a pressure rate of dP PF /dT is provided, at least one of the following is held true:

a) said P PF is in a range of about 0 to about 10 barg;

b) said V PF is in a range of about 1 to about 50 ml;

c) said V sub is in a range of about 0.01 to about 7 ml;

d) said D is in a range of 0.2 to about 6 mm;

e) said pressure rate,

dP

dT

;

and

f) said pressure rate greater than about 0.001 barg/ms.

12. The device of claim 1 , wherein a particle size of the bi-modal spray pattern is distributed such that it includes a first peak associated with a first particle size greater than 100 μm and a second peak associated with a second particle size less than 100 μm.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2025
From: SIPNOSE LTD.
To: APTARGROUP, INC.
Reel/Frame 072206/0790 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2021
From: SHAHAF, DANIEL; SHICHOR, IRIS
To: SIPNOSE LTD.
Reel/Frame 055046/0250 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2020
From: SHAHAF, DANIEL; SHICHOR, IRIS
To: SIPNOSE LTD.
Reel/Frame 053728/0853 →
Priority Claims (1)
DE 2020131057150 · Dec 16, 2013 · national
Continuity (13)
Continuation In Part 15982996 · May 17, 2018
Continuation In Part 14733143 · Jun 8, 2015
Continuation In Part 16810096 · Mar 5, 2020
Continuation In Part 15982630 · May 17, 2018
Continuation In Part 14733143 · Jun 8, 2015
Continuation In Part 14433048
Provisional Application 62117986 · Feb 19, 2015
Provisional Application 62077246 · Nov 9, 2014
Provisional Application 62526386 · Jun 29, 2017
Provisional Application 62507816 · May 18, 2017
Provisional Application 61868614 · Aug 22, 2013
Provisional Application 61868627 · Aug 22, 2013
Related Publication 20200289768A1 · Sep 17, 2020
References Cited (136)
US 462990A · Oppenheimer · 1891 [cited by applicant]
US 3921637A · Bennie et al. · 1975 [cited by applicant]
US 4017007A · Riccio · 1977 [cited by applicant]
US 4114615A · Wetterlin et al. · 1978 [cited by applicant]
US 4620670A · Hughes · 1986 [cited by applicant]
US 5048729A · Pritchard · 1991 [cited by examiner]
US 5307953A · Regan · 1994 [cited by applicant]
US 5740794A · Smith et al. · 1998 [cited by applicant]
US 6123228A · Hippensteel · 2000 [cited by applicant]
US 6186141B1 · Pike et al. · 2001 [cited by applicant]
US 6398074B1 · Bruna et al. · 2002 [cited by applicant]
US 6708846B1 · Fuchs et al. · 2004 [cited by applicant]
US 6971385B1 · Flora · 2005 [cited by examiner]
US 7497390B2 · Beller · 2009 [cited by applicant]
US 7726308B1 · Flora · 2010 [cited by applicant]
US 7802569B2 · Yeates et al. · 2010 [cited by applicant]
US 7900659B2 · Whitley et al. · 2011 [cited by applicant]
US 8360056B2 · Ishizeki et al. · 2013 [cited by applicant]
US 20010008637A1 · Hochrainer et al. · 2001 [cited by applicant]
US 20020023641A1 · Stadelhofer · 2002 [cited by applicant]
US 20020092520A1 · Casper · 2002 [cited by examiner]
US 20020092521A1 · Sullivan et al. · 2002 [cited by applicant]
US 20020092524A1 · Lockhart et al. · 2002 [cited by applicant]
US 20030079743A1 · Genova et al. · 2003 [cited by applicant]
US 20030127533A1 · Stihl · 2003 [cited by applicant]
US 20030181917A1 · Gertner · 2003 [cited by applicant]
US 20030187404A1 · Waldenburg · 2003 [cited by applicant]
US 20030209455A1 · Pynson et al. · 2003 [cited by applicant]
US 20040050885A1 · Stradella · 2004 [cited by applicant]
US 20040153033A1 · Mazzoni · 2004 [cited by applicant]
US 20050028812A1 · Djupesland · 2005 [cited by applicant]
US 20060067911A1 · Nilsson · 2006 [cited by applicant]
US 20060107957A1 · Djupesland · 2006 [cited by applicant]
US 20060151629A1 · Vedrine et al. · 2006 [cited by applicant]
US 20060213514A1 · Price et al. · 2006 [cited by applicant]
US 20060254583A1 · Deboeck et al. · 2006 [cited by applicant]
US 20060254585A1 · Ishizeki et al. · 2006 [cited by applicant]
US 20070051362A1 · Sullivan et al. · 2007 [cited by applicant]
US 20070060868A1 · Tsutsui · 2007 [cited by applicant]
US 20070125371A1 · Djupesland · 2007 [cited by applicant]
US 20070151562A1 · Jones et al. · 2007 [cited by applicant]
US 20070154407A1 · Peters et al. · 2007 [cited by applicant]
US 20070256688A1 · Schuster et al. · 2007 [cited by applicant]
US 20080029084A1 · Costantino · 2008 [cited by examiner]
US 20080092887A1 · Hodson et al. · 2008 [cited by applicant]
US 20080210229A1 · Corbacho · 2008 [cited by applicant]
US 20090166379A1 · Wright et al. · 2009 [cited by applicant]
US 20090285849A1 · Barsanti et al. · 2009 [cited by applicant]
US 20090314293A1 · Djupesland · 2009 [cited by applicant]
US 20100083963A1 · Wharton et al. · 2010 [cited by applicant]
US 20100282246A1 · Djupesland · 2010 [cited by applicant]
US 20100331765A1 · Sullivan et al. · 2010 [cited by applicant]
US 20110048414A1 · Hoekman · 2011 [cited by applicant]
US 20110088690A1 · Djupesland et al. · 2011 [cited by applicant]
US 20110168172A1 · Patton · 2011 [cited by applicant]
US 20110283996A1 · Abrams · 2011 [cited by applicant]
US 20120291779A1 · Haartsen et al. · 2012 [cited by applicant]
US 20130096495A1 · Holmqvist et al. · 2013 [cited by applicant]
US 20130180524A1 · Shahaf · 2013 [cited by applicant]
US 20130267864A1 · Addington et al. · 2013 [cited by applicant]
US 20130299607A1 · Wilkerson et al. · 2013 [cited by applicant]
US 20130345673A1 · Ferreri et al. · 2013 [cited by applicant]
US 20140060532A1 · Hodges et al. · 2014 [cited by applicant]
US 20150122257A1 · Winkler et al. · 2015 [cited by applicant]
US 20150144129A1 · Djupesland · 2015 [cited by applicant]
US 20150174343A1 · Muellinger et al. · 2015 [cited by applicant]
US 20150209325A1 · Najarian et al. · 2015 [cited by applicant]
US 20150258287A1 · Shahaf et al. · 2015 [cited by applicant]
US 20150297845A1 · Shahaf et al. · 2015 [cited by applicant]
US 20160129205A1 · Shahaf et al. · 2016 [cited by applicant]
US 20180072480A1 · Genosar · 2018 [cited by applicant]
US 20180110922A1 · Dunki-Jacobs et al. · 2018 [cited by applicant]
US 20190015613A1 · Shahaf et al. · 2019 [cited by applicant]
US 20190060168A1 · Koska · 2019 [cited by applicant]
US 20200197631A1 · Stedman et al. · 2020 [cited by applicant]
US 20200197633A1 · Shahaf et al. · 2020 [cited by applicant]
US 20200289768A1 · Shahaf et al. · 2020 [cited by applicant]
US 20200289769A1 · Poullain · 2020 [cited by applicant]
US 20200306463A1 · Shahaf et al. · 2020 [cited by applicant]
CN 1981886 · 2007 [cited by applicant]
CN 104520198 · 2015 [cited by applicant]
CN 107580513 · 2018 [cited by applicant]
DE 19502725 · 1996 [cited by applicant]
DE 1970806 · 1998 [cited by applicant]
DE 202013105715U1 · 2014 [cited by applicant]
EP 1023098B1 · 2004 [cited by applicant]
EP 1752176A1 · 2007 [cited by applicant]
EP 2002856A1 · 2008 [cited by applicant]
EP 2030645A1 · 2009 [cited by applicant]
EP 2922770 · 2015 [cited by applicant]
GB 724974 · 1953 [cited by applicant]
GB 2415376A · 2005 [cited by applicant]
JP 2002505981A · 2002 [cited by applicant]
WO 9012567A1 · 1990 [cited by applicant]
WO WO02505981 · 1999 [cited by applicant]
WO WO9946055 · 1999 [cited by applicant]
WO WO9958180 · 1999 [cited by applicant]
WO WO02055133A2 · 2002 [cited by applicant]
WO WO02060517A2 · 2002 [cited by applicant]
WO WO2009002267 · 2008 [cited by applicant]
WO 2012029064A1 · 2012 [cited by applicant]
WO WO2012105236A1 · 2012 [cited by applicant]
WO 20130128447A1 · 2013 [cited by applicant]
WO WO2015025324A1 · 2015 [cited by applicant]
WO WO2016054742 · 2016 [cited by applicant]
WO WO2016071914A1 · 2016 [cited by applicant]
WO WO2016199135A1 · 2016 [cited by applicant]
WO WO2018051371 · 2018 [cited by applicant]
WO WO2019003216A1 · 2019 [cited by applicant]
WO WO2019073165 · 2019 [cited by applicant]
WO WO2019079335 · 2019 [cited by applicant]
WO WO2019220443A1 · 2019 [cited by applicant]
WO WO2020154182 · 2020 [cited by applicant]
Affidavit of Ms. Lia Kaufman dtd Aug. 3, 2020, pp. 1-9, with Facts and Arguments brief, published Aug. 7, 2020 in the Register of the Opposition proceedings in EP 3400047 B1, available at https://register.epo.org/applic… [cited by applicant]
Pharmaseed Ltd., Author: N/A, Title: Brain and Blood PK Profile Following Intranasal Topirmate Administration—Comparison Between SipNose and Other Nasal Devices (“Pharmaseed”), pp. 1-43, with Petition in response to Pat… [cited by applicant]
Sipnose, Author: N/A, Title: Preclinical Device S1A2NP8 Batch Release Form (“SipNose”), pp. 1-2, with Petition (21 pages total), published Mar. 4, 2021 in the Register of the Opposition proceedings in EP 3400047 B1, ava… [cited by applicant]
Affidavit of Lia Kaufman. [cited by applicant]
Brain and Blood PK Profile Following Intranasal Topirmate Administration—Comparison Between SIPNOSE and other Nasal Devices. [cited by applicant]
Sample Batch Release Form—S1A2NP8 Pre-Clinical Devices. [cited by applicant]
Damm et al., “Intranasal Volume and Olfactory Function”, Chemical Senses, 2002, pp. 831-839, vol. 27, Oxford University Press. [cited by applicant]
Derendorf et al., “Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications”, Allergy, 2008, pp. 1292-1300, vol. 63, 2008 Blackwell Munksgaard. [cited by applicant]
Doose et al., “Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, A novel antiepileptic drug”, Journal of Clinical Pharmacology, 1996, pp. 884-891, vol. 36. [cited by applicant]
Ganger et al., “Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa”, Pharmaceutics, 2018, pp.… [cited by applicant]
Khan et al., “Progress in brain targeting drug delivery system by nasal route”, Journal of Controlled Release, 2017, pp. 364-389, vol. 268, Elsevier B.V. [cited by applicant]
Lammi et al., “Treatment with intranasal iloprost reduces disease manifestations in a murine model of previously established COPD”, The American Journal of Physiology—Lung Cellular and Molecular Physiology, 2016, pp. L6… [cited by applicant]
Leombruni et al., “Treatment of obese patients with binge eating disorder using topiramate: a review”, Neuropsychiatric Disease and Treatment, 2009, pp. 385-392, vol. 5, Dove Medical Press Ltd. [cited by applicant]
Massolt et al., “Appetite suppression through smelling of dark chocolate correlates with changes in ghrelin in young women”, Regulatory Peptides, 2010, pp. 81-86, vol. 161, 2010 Elsevier B.V. [cited by applicant]
Puhakka et al., “The common cold: Effects of intranasal fluticasone propionate treatment”, The Journal of Allergy and Clinical Immunology, 1998, pp. 726-731, vol. 101, No. 6, Part 1, Mosby, Inc. [cited by applicant]
Ramaekers et al., “Odors: appetizing or satiating? Development of appetite during odor exposure over time”, International Journal of Obesity, 2014, pp. 650-656, vol. 38, 2014 Macmillan Publishers Limited. [cited by applicant]
Scheibe et al., “Intranasal Administration of Drugs”, Archives of Otolaryngology—Head & Neck Surgery, Jun. 2008, pp. 643-646, vol. 134, No. 6, 2008 American Medical Association. [cited by applicant]
Schiffman et al., “Taste and smell perception affect appetite and immunity in the elderly”, European Journal of Clinical Nutrition, 2000, pp. S54-S63, Suppl 3, 2000 Macmillan Publishers Ltd. [cited by applicant]
Schriever et al., “Size of nostril opening as a measure of intranasal volume”, Physiology & Behavior, 2013, pp. 3-5, vol. 110-111, 2012 Elsevier Inc. [cited by applicant]
Yeomans, “Olfactory influences on appetite and satiety in humans”, Physiology and Behavior, 2006, pp. 1-14, vol. 89, No. 1. [cited by applicant]
PCT International Preliminary Report on Patentability for International Application No. PCT/IL2014/050752, dated Feb. 23, 2016. [cited by applicant]
PCT International Search Report for International Application No. PCT/IL2014/050752, dated Dec. 18, 2014. [cited by applicant]
PCT International Written Opinion for International Application No. PCT/IL2014/050752, dated Dec. 18, 2014. [cited by applicant]